Dr. Reshma Kewalramani, Chief Executive Officer and President of Vertex Pharmaceuticals, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on 8 January 2024.
Dr Reshma Kewalramani, CEO and President of Vertex Pharmaceuticals, described the approval of Casgevy by the Food and Drug Administration as 'momentous'. Casgevy alters the faulty gene that causes sickle cell disease and this results in the production of functioning hemoglobin in the body.
Reshma Kewalramani, CEO of Vertex, has described Britain’s approval of Casgevy and the first regulatory approval of a CRISPR-based therapy in the world, as a historic day for medicine and science.
Janelle Nanos tells the success story of Vertex Chief Executive Officer Reshma Kewalramani: from transplant nephrologist to heading biotech giant Vertex.
Reshma Kewalramani, Vertex CEO, has been named as the 2023 recipient of the Distinguished Alumni Award from Boston University Medical Campus for her outstanding achievements in the fields of medicine, healthcare and biotechnology.
